Company intelligence / Profile preview

Ingredia

Ownership: Private
Employees: ~470
Development stage: Other

Overview

Ingredia's clinically studied products include Lactium® for stress reduction, Prodiet® Lactoferrin for immune/digestive support, and Pep2Dia® to help regulate blood sugar. These are commercialized as functional food/nutraceutical ingredients with clinical evidence supporting efficacy in their respective wellness areas. No pharmaceutical clinical trial pipeline exists; all products are marketed as food or supplement ingredients.

Therapeutic areas: GastroenterologyPsychiatryImmunologyEndocrinology
Modalities: ProteinPeptidesNatural extractSmall moleculeBiologic
Industry: Food & Nutrition

Partnerships

Lactocore Group – research partnership to develop new functional foods based on milk peptide hydrolysates targeting mood disorders and metabolic conditionsWWF – sustainability partnership for responsible production practices

Beyond the preview

Go deeper on Ingredia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ingredia.

Explore the full profile